Innovative Trends That Drive AAV Capture and Empty-Full Separation

by Ratish Krishnan and Oliver Rammo | March 22, 2023

Ratish Krishnan and Oliver Rammo share their thoughts on the need for a more nuanced understanding of AAV capture and empty–full separation, and the trends driving innovation in this area.

Below are some of the questions discussed during the podcast:

What are the challenges in AAV empty-full separation?
How well understood is empty–full capsid separation in the gene therapy industry? What are some of the misconceptions?
How can analytics drive innovation in this area?
Looking to the future, how do you expect to see technology for AAV capture and empty–full separation evolve over the next 5 years?
How will future trends in AAV capsid design and production affect purification?

Click HERE to access the content

Ratish Krishnan

Senior Strategy Consultant

Ratish Krishnan is a Senior Strategy Consultant in the Novel Modalities BioProcessing group for the Americas. He is passionate about providing solutions to bring treatments to market. A Process Development Scientist by background, he has over 13 years of experience in vaccine, monoclonal antibodies and viral vector modalities from pre-clinical to late stage process characterization, validation and commercialization activities such as BLA authoring.

Oliver Rammo

Oliver Rammo is leading the Novel Modality segment in the Purification R&D Group responsible for the development of novel purification strategies for the Viral and Gene Therapy market. Prior to his current role, he worked as Laboratory Manager and Application Engineer for the MilliporeSigma Life Science division. He joined

Merck KGaA, Darmstadt, Germany

MilliporeSigma

in 2012, working for Performance Materials Advanced Technologies in the field of printing formulations for photovoltaic applications. Oliver holds a BSc in Applied Life Science from the University of Kaiserslautern and an MSc in Molecular Biotechnology from the University of Frankfurt.